SUPPLEMENTARY SUBJECTS/MATERIALS AND METHODS

Standard protocol approvals, registration, and patient consents
Fingolimod-treated MS patients, untreated MS patients and healthy donors were recruited at the Department of Neurology, University Hospital Münster. The study was approved by the local ethics committee. CSF specimens were taken for medical reasons and remaining material was used for analysis as approved by the ethics committee. Written informed consent was obtained from all participants of the study.
The study was performed according to the Declaration of Helsinki.
CSF-controls
In addition to the clinical classification the inclusion criteria for the Ctrl. group comprised the following laboratory parameters, defining a non-inflammatory CSF: total cell count < 5 cells/µL, protein concentration < 500 mg/L, lactate concentration < 2 mM, integrity of the blood/CSF barrier (determined by the CSF/serum albumin quotient) and absence of intrathecal Ig synthesis (CSF-specific OCB). As part of clinical routine analyses, B cell counts in peripheral blood and CSF of 41 MS patients and 25 Ctrls. (not included in Table 1 and in the above-specified patients and Controls) were determined via flow cytometry. For our study an additional flow cytometric measurement with blood and CSF samples of a small group of patients was included.
Antibodies, cells and reagents
All antibodies used in this study are listed in Supplementary Table 1 
Biomaterials
PBMC were isolated from EDTA blood by density-gradient centrifugation with Lymphoprep™ (STEMCELL technologies, Cologne, Germany), according to the manufacturer's protocol. Cells were then either used directly or cryo-preserved in liquid nitrogen using freezing medium (50 % RPMI, 40 % FCS, 10 % DMSO) in concentrations of 1 x 10 7 cells/mL. After thawing at 37 °C, PBMC were added to 10 mL RPMI (Life technologies, Darmstadt, Germany) and centrifuged to remove the DMSO.
For assessing absolute cell counts and composition of B-cell subpopulations in blood and CSF, fresh blood and CSF samples were treated with VersaLyse™ (Beckman Coulter), according to the manufacturer's protocol. The obtained immune cells were then directly subjected to flow-cytometric analysis.
For assays, in which pure B cells were used, PBMC were subjected to magnetassisted cell-sorting (Miltenyi Biotech GmbH, Bergisch Gladbach, Germany), using CD19 MicroBeads (Miltenyi) according to the manufacturer's protocol. 
Cytokine secretion assay
HBMEC culture and transmigration assay
Primary HBMEC were cultured in ECM on 4 mg/mL fibronectin (Sigma-Aldrich, Munich, Germany).
Transmigration assays were performed as previously described. 28 In brief: Polyester membrane-bottom transwell inserts (3.0 µm pore size, Corning GmbH, Wiesbaden, Germany) were coated with 100 mg/mL fibronectin for at least 3 h. Then, 3 x 10 4 HBMEC were added and cultured to confluence.
For transmigration under inflammatory conditions, Interferon γ (500 IU/mL) and TNFα (500 IU/mL) were added into the lower compartment of the transwells, one day prior to the transmigration assay. The above-described procedure was carried through for the obtained wholelymphocyte counts, as well. Only they were normalized to the average lymphocyte counts of the Ctrl.-group.
Flow cytometry
For surface-molecule staining, cells were washed with staining buffer (PBS, 0,1 % BSA, 200 mM EDTA) and subsequently stained with fluorescent-dye-labelled monoclonal antibodies for 10 minutes at room temperature. After washing once with staining buffer, cells were analyzed with a Gallios flow-cytometer (Beckman Coulter).
To assess absolute cell counts in blood and CSF 20 µL of flow-count fluorospheres 
Statistics
For statistical analysis, an unpaired, 2-tailed student's t-test was performed. Values of p < 0,05 were considered to be significant. 
